Huntington's Disease Clinical Trial
Official title:
The Effects of Music Therapy on Depression, Chorea and Other Symptoms of Huntington's Disease
The purpose of this study is primarily to assess the ability of a music therapy program to improve holistically the psychological, somatic, and social symptoms of patients with Huntington 's disease (HD). We hope to demonstrate the benefits of applying music therapy interventions to the management methods of HD, thus paving the way for the development of an effective music therapy program for individuals with HD.
ABSTRACT
Background: Recent studies show that music therapy helps improve the symptomatic
manifestations of Parkinson's Disease. Few studies have looked at music therapy as a
treatment for the psychiatric, cognitive and motor symptoms of patients with Huntington's
disease (HD).
Objective: To examine the feasibility and tolerability of a treatment program of music
therapy for patients with Huntington's disease. Also, to determine if music therapy improves
the mood and motor features of HD while improving quality of life.
Methods: Subjects with HD were recruited to participate in a six-week study that included
one individual, half-hour music therapy session and one hour-long group session per week.
The music therapy protocols were adapted from the Colorado State University's Neurological
Music Therapy program and were targeted to HD symptoms including balance and posture, fine
motor skills, memory and attention, vocalizations, and mood. In particular the protocols
included Rhythmic Auditory Stimulation (RAS), Pattern Sensory Enhancement (PSE), and
Therapeutic Instrumental Music Playing (TIMP). Primary outcome of tolerability was to be
assessed by the subjects' adherence to the therapeutic protocol, attendance, and the results
of an exit survey inquiring about their feelings toward the use of music therapy in HD. A
secondary outcome of the study was the change in the Unified Huntington's Disease Rating
Scale (UHDRS) score between baseline and study completion.
Results: Five subjects were recruited for study participation (one female and four males).
Music therapy was found to be a tolerable and feasible treatment for patients with HD (100%
adherence and 98% attendance). Exit surveys demonstrated strongly positive feelings towards
the music therapy treatment program in four of the five subjects (one survey was completed
with contradictory answers by the subject). While there was improvement in UHDRS scores for
finger tapping, pronation/supination and the Luria, these changes did not achieve
statistical significance with the small sample size in this study.
Conclusions: Music therapy was well tolerated among subjects with HD in this small study.
Future studies are now being planned to look at the efficacy of this intervention in a
larger population of HD subjects.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04120493 -
Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02956148 -
Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion Carriers
|
Early Phase 1 | |
Terminated |
NCT02494778 -
A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease
|
Phase 2 | |
Completed |
NCT02197130 -
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
|
Phase 2 | |
Completed |
NCT02208934 -
Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers
|
Phase 1 | |
Completed |
NCT02216474 -
Brain Stimulation in Movement Disorders
|
N/A | |
Completed |
NCT01806896 -
Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease
|
Phase 2 | |
Completed |
NCT01502046 -
Neuroprotection by Cannabinoids in Huntington's Disease
|
Phase 2 | |
Terminated |
NCT00712426 -
Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)
|
Phase 3 | |
Completed |
NCT00670709 -
Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease
|
||
Completed |
NCT00029874 -
Minocycline in Patients With Huntington's Disease
|
Phase 1/Phase 2 | |
Terminated |
NCT02231580 -
Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients
|
Phase 2 | |
Completed |
NCT02215616 -
A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod
|
Phase 2 | |
Not yet recruiting |
NCT02551705 -
Functional Imaging of Social Cognition in Premanifest Huntington's Disease
|
N/A | |
Active, not recruiting |
NCT02101957 -
Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)
|
Phase 2/Phase 3 | |
Completed |
NCT01521832 -
Escalating Dose Study in Healthy Volunteers With SEN0014196
|
Phase 1 | |
Completed |
NCT00990613 -
A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin
|
Phase 1 | |
Completed |
NCT00975481 -
A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users
|
Phase 1 | |
Completed |
NCT00387270 -
Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT00095355 -
Effects of Lithium and Divalproex`on Brain-Derived Neurotrophic Factor in Huntington's Disease
|
Phase 2 |